Goldman Sachs: These 2 ‘Strong Buy’ Stocks Are Must-Watch Names, , on November 4, 2020 at 3:29 pm

By ILP
On 11/04/2020
In Financial News
Tags:

And just like that, Election Day has come and gone. After Americans took to the polls, Wall Street is anxiously waiting to see if a clear winner will be named. According to Wall Street pros, a declared winner, regardless of who it is, would be beneficial to the markets. That said, some argue volatility in the days after the election is not out of the question. To this end, the pros recommend taking advantage of any quick dips to pick up compelling names.Bearing this in mind, we turned to investment firm Goldman Sachs for some inspiration. Looking at two stocks in particular, both have been deemed must-watch names by the firm’s analysts. Running the tickers through TipRanks’ database, we found out that each boasts a “Strong Buy” analyst consensus. Moderna (MRNA)Biotech Moderna has landed under the spotlight since the onset of the pandemic, with it taking a leading position in the race to develop a COVID-19 vaccine. Ahead of the first Phase 3 interim data readout for its experimental vaccine candidate, Goldman Sachs is pounding the table.According to management, the Phase 3 COVE study evaluating its COVID-19 vaccine candidate, mRNA-1273, is on track for the first interim analysis this month, and the second interim analysis at 106 events will most likely come in December.Looking more closely at the study, it is fully enrolled, as of October 22, and 25,654 participants have received the second vaccination. The company has highlighted the study’s diversity, with 37% of subjects coming from diverse communities and 25% of participants over 65 years old. Additionally, 17% of participants have comorbidities and over 8,000 participants have chronic conditions like diabetes or severe obesity.As second dose two-month median follow-up (15,000 participants) safety data is expected in the back half of November, Goldman Sachs’ Salveen Richter argues an emergency use authorization (EUA) could come by YE20. “Importantly, we highlight management’s confidence in achieving these timelines, which is supported by trends in infection rates and internal models,” she explained.On top of this, MRNA already has several supply contracts in place for the experimental vaccine, with it recently revealing that the Ministry of Health, Labour and Welfare of Japan and Takeda (TAK) has agreed to purchase and distribute 50 million doses. It’s also working to ink deals with the European Union, COVAX, as well as with many other countries.All in all, MRNA received $1.1 billion of customer deposits for the supply of mRNA-1273 in Q3 2020. In the U.S., the agreement will begin after the candidate is granted an EUA.What’s more, based on the “ease of administration and storage,” MRNA says “vaccine can be deployed in multiple settings including hospitals, physician’s offices, nursing homes and immunization centers.” Beyond mRNA-1273, the rest of its pipeline is also progressing well, in the five-star analyst’s opinion.Taking all of this into consideration, Richter maintains a Buy rating and bumps up the price target from $107 to $108. This target conveys her confidence in MRNA’s ability to climb 52% higher in the next year. (To watch Richter’s track record, click here)In general, other analysts are on the same page. 10 Buys, 1 Hold and 1 Sell add up to a Strong Buy consensus rating. With an average price target of $96.91, the upside potential comes in at ~37%. (See Moderna stock analysis on TipRanks)Herc Holdings (HRI)As one of the largest equipment rental companies in North America, Herc Holdings meets the needs of customers through its approximately 270 locations. With its recovery gaining significant traction, Goldman Sachs thinks that now is the time to get in on the action.Goldman Sachs analyst Jerry Revich believes its Q3 earnings release demonstrates “an accelerating utilization recovery, steady pricing, and strong cost control.” According to the five-star analyst, the key takeaway was that utilization beat his estimate by 200 basis points. In addition, HRI guided for fleet on rent growth of approximately 1.4% sequentially in Q4, versus normal seasonality of -2%, with Revich also calling capex “disciplined.”During the quarter, fleet on rent increased 21%-plus sequentially compared to 12%-plus on average for the past three years, driven by a recovery in the non-residential commercial markets, particularly within the emergency response space.As a result, the analyst estimates that Q4 utilization will only be down 200 basis points year-over-year, compared to the 800-basis point drop in Q2. As capex and fleet size guidance remains unchanged, Revich thinks supply is “tight.”Although Q3 EBITDA of $197 million beat Revich and the Street’s estimates, implied Q4 EBITDA guidance of $171 million landed 8% below pre-result consensus EBITDA, with shares falling in response. However, Revich points out that with “fleet on rent set to rise sequentially and pricing stable, both factors that are well ahead of normal seasonality,” he argues “the guidance of a sequential decline in EBITDA reflects management’s conservatism in the second quarter of a recovery following a deep trough.”To this end, the analyst’s Q4 EBITDA estimate is 16% above the high-end of guidance. Revich added, “We believe visibility on a cyclical recovery significantly improved today despite the conservative guidance.”In line with his optimistic approach, Revich sides with the bulls, reiterating a Buy rating. He also puts a $62 price target on the stock, bringing the upside potential to 41%. (To watch Revich’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been issued in the last three months. Therefore, the message is clear: HRI is a Strong Buy. Given the $55.25 average price target, shares could surge 25% in the next year. (See HRI stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Goldman Sachs: These 2 ‘Strong Buy’ Stocks Are Must-Watch NamesAnd just like that, Election Day has come and gone. After Americans took to the polls, Wall Street is anxiously waiting to see if a clear winner will be named. According to Wall Street pros, a declared winner, regardless of who it is, would be beneficial to the markets. That said, some argue volatility in the days after the election is not out of the question. To this end, the pros recommend taking advantage of any quick dips to pick up compelling names.Bearing this in mind, we turned to investment firm Goldman Sachs for some inspiration. Looking at two stocks in particular, both have been deemed must-watch names by the firm’s analysts. Running the tickers through TipRanks’ database, we found out that each boasts a “Strong Buy” analyst consensus. Moderna (MRNA)Biotech Moderna has landed under the spotlight since the onset of the pandemic, with it taking a leading position in the race to develop a COVID-19 vaccine. Ahead of the first Phase 3 interim data readout for its experimental vaccine candidate, Goldman Sachs is pounding the table.According to management, the Phase 3 COVE study evaluating its COVID-19 vaccine candidate, mRNA-1273, is on track for the first interim analysis this month, and the second interim analysis at 106 events will most likely come in December.Looking more closely at the study, it is fully enrolled, as of October 22, and 25,654 participants have received the second vaccination. The company has highlighted the study’s diversity, with 37% of subjects coming from diverse communities and 25% of participants over 65 years old. Additionally, 17% of participants have comorbidities and over 8,000 participants have chronic conditions like diabetes or severe obesity.As second dose two-month median follow-up (15,000 participants) safety data is expected in the back half of November, Goldman Sachs’ Salveen Richter argues an emergency use authorization (EUA) could come by YE20. “Importantly, we highlight management’s confidence in achieving these timelines, which is supported by trends in infection rates and internal models,” she explained.On top of this, MRNA already has several supply contracts in place for the experimental vaccine, with it recently revealing that the Ministry of Health, Labour and Welfare of Japan and Takeda (TAK) has agreed to purchase and distribute 50 million doses. It’s also working to ink deals with the European Union, COVAX, as well as with many other countries.All in all, MRNA received $1.1 billion of customer deposits for the supply of mRNA-1273 in Q3 2020. In the U.S., the agreement will begin after the candidate is granted an EUA.What’s more, based on the “ease of administration and storage,” MRNA says “vaccine can be deployed in multiple settings including hospitals, physician’s offices, nursing homes and immunization centers.” Beyond mRNA-1273, the rest of its pipeline is also progressing well, in the five-star analyst’s opinion.Taking all of this into consideration, Richter maintains a Buy rating and bumps up the price target from $107 to $108. This target conveys her confidence in MRNA’s ability to climb 52% higher in the next year. (To watch Richter’s track record, click here)In general, other analysts are on the same page. 10 Buys, 1 Hold and 1 Sell add up to a Strong Buy consensus rating. With an average price target of $96.91, the upside potential comes in at ~37%. (See Moderna stock analysis on TipRanks)Herc Holdings (HRI)As one of the largest equipment rental companies in North America, Herc Holdings meets the needs of customers through its approximately 270 locations. With its recovery gaining significant traction, Goldman Sachs thinks that now is the time to get in on the action.Goldman Sachs analyst Jerry Revich believes its Q3 earnings release demonstrates “an accelerating utilization recovery, steady pricing, and strong cost control.” According to the five-star analyst, the key takeaway was that utilization beat his estimate by 200 basis points. In addition, HRI guided for fleet on rent growth of approximately 1.4% sequentially in Q4, versus normal seasonality of -2%, with Revich also calling capex “disciplined.”During the quarter, fleet on rent increased 21%-plus sequentially compared to 12%-plus on average for the past three years, driven by a recovery in the non-residential commercial markets, particularly within the emergency response space.As a result, the analyst estimates that Q4 utilization will only be down 200 basis points year-over-year, compared to the 800-basis point drop in Q2. As capex and fleet size guidance remains unchanged, Revich thinks supply is “tight.”Although Q3 EBITDA of $197 million beat Revich and the Street’s estimates, implied Q4 EBITDA guidance of $171 million landed 8% below pre-result consensus EBITDA, with shares falling in response. However, Revich points out that with “fleet on rent set to rise sequentially and pricing stable, both factors that are well ahead of normal seasonality,” he argues “the guidance of a sequential decline in EBITDA reflects management’s conservatism in the second quarter of a recovery following a deep trough.”To this end, the analyst’s Q4 EBITDA estimate is 16% above the high-end of guidance. Revich added, “We believe visibility on a cyclical recovery significantly improved today despite the conservative guidance.”In line with his optimistic approach, Revich sides with the bulls, reiterating a Buy rating. He also puts a $62 price target on the stock, bringing the upside potential to 41%. (To watch Revich’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been issued in the last three months. Therefore, the message is clear: HRI is a Strong Buy. Given the $55.25 average price target, shares could surge 25% in the next year. (See HRI stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Contact Us

Please use our Instant Quote form to see if you're pre-qualified for a non-recourse stock loan, or if you have any questions or feedback, please email, call or chat with us.

deals@internationalliquiditypartners.com

+44 20 3994 1588

Headquarters: Hunkins Waterfront Plaza, Charlestown, Nevis

Open 24 hours a day / 7 days a week / 365 days a year

 

 

 

Frequently Asked Questions

What Is Securities-Based Lending?
Securities-based lending, or a stock loan, is the practice of using market investments such as stocks, ETF’s, warrants, bonds, or real estate investment trusts as collateral for a loan.
How much money can I get for my securities?
Borrow up to 80% of the value of your pledged investments giving you the capital you need to expand your business, purchase real estate, or tackle a costly project.
What happens if my securities lose value?
With a non-recourse stock loan, you can walk away from your securities at any time and keep the loan money with no negative credit consequences even if the investments lose value.
Is my information safe with ILP?
We pride ourselves on outstanding service and make client confidentiality our top priority. You can always be absolutely certain your information is safe with us.
How long does it take for the disbursement of funds?
Most of the transactions we process take less than 7 days from application to the disbursement of funds giving you cash quickly when you need it most.
What credit score do I need to qualify?
There are no credit checks or personal guarantees necessary with our services. Your pledged securities are the only collateral required for the loan you receive.

Instant Quote

Please fill out your information to see if you are pre-qualified.

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

International Liquidity Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

International Liquidity Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with International Liquidity Partners, LLC’s internal lending policies. International Liquidity Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Nevis Office

Main Street
Hunkins Waterfront Plaza
Charlestown, Nevis

New York Office

Coming Soon!

Follow Us

Market Coverage